MDA-MB-231 cells were treated with three concentrations of the reversible EGFR inhibitors gefitinib and erlotinib based on published IC50 values for breast cancer cell lines [41–44] in combination with 5μM JNK-IN-8. This evidence concerns the gene EGFR and breast carcinoma.